Comparison of the clinical prediction model PREMM1,2,6 and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer

Gut

Volumn 62, Issue 2, 2013, Pages 272-279

  Kastrinos, Fay ^a,b   Steyerberg, Ewout W ^c   Balmaña, Judith ^d   Mercado, Rowena ^e   Gallinger, Steven ^f,g   Haile, Robert ^h   Casey, Graham ^h   Hopper, John L ⁱ   LeMarchand, Loic ^j   Lindor, Noralane M ^k   Newcomb, Polly A ^l,m   Thibodeau, Stephen N ^k   Syngal, Sapna ^e,n,o  

^a Howard Hughes Medical Institute   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^k MAYO CLINIC   (United States)

^l Fred Hutchinson Cancer Research Center   (United States)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MLH1 GENE; MSH2 GENE; MSH6 GENE; MUTATIONAL ANALYSIS; PREDICTION; PREMM 1,2,6; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; COHORT STUDIES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; REGISTRIES; ROC CURVE; YOUNG ADULT;

EID: 84872071989     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301265     Document Type: Article

References (35)

1. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999;36:801-18. (Pubitemid 29520569)
2. Lynch HT, Boland CR, Gong G, et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 2006;14:390-402.
3. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26:5783-8.
4. Balmaña J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 Mutations in Lynch syndrome. JAMA 2006;296:1469-78. (Pubitemid 44465511)
5. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch repair genes in colon cancers. N Engl J Med 2006;354:2751-63. (Pubitemid 43974193)
6. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006;296:1479-87. (Pubitemid 44465512)
7. Reyes CM, Allen BA, Terdiman JP, et al. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 2002;95:1848-56. (Pubitemid 35222163)
8. Piñol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986-94. (Pubitemid 40570892)
9. Rodriguez-Moranta F, Castells A, Andreu M, et al Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol 2006;101 :1104-11. (Pubitemid 43725327)
10. Julié C, Trésallet C, Brouquet A, et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 2008;103 :2825-35; quiz 2836.
11. Balmaña J, Balaguer F, Castellví-Bel S, et al. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 2008;45:557-63.
12. Mueller J, Gazzoli I, Bandipalliam P, et al. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases. Cancer Res 2009;69:7053-61.
13. Newcomb PA, Baron J, Cotterchio M, et al Colon Cancer Family Registry. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2331-43. (Pubitemid 351196365)
14. Poynter JN, Siegmund KD, Weisenberger DJ, et al Colon Cancer Family Registry Investigators. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 2008;17:3208-15.
15. Cicek MS, Lindor NM, Gallinger S, et al . Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors: results from the Colon Cancer Family Registry. J Mol Diagn 2011; 13:271-81.
16. Steyerberg EW, Balmaña J, Stockwell DH, et al. Data reduction for prediction: a case study on robust coding of age and family history for the risk of having a genetic mutation. Stat Med 2007;26:5545-56. (Pubitemid 351193580)
17. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010;21:128-38.
18. Marshall A, Altman DG, Holder RL, et al. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 2009;9:57-64.
19. Rodriquez-Bigas MA, Boland CR, Hamilton SR, et al. An NCI workshop on HNPCC: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.
20. 1,2,6 model predicts risk of MLH1, MSH2 and MSH6 germline mutations based on cancer history. Gastroenterology 2011;140:73-81.
21. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 2011;4:9-22.
22. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-6. (Pubitemid 29258894)
23. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8. (Pubitemid 38256271)
24. Syngal S, Fox EA, Eng C, et al. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000;37:641-5.
25. Green RC, Parfrey PS, Woods MO, et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 2009;101:331-40.
26. Monzon JG, Cremin C, Armstrong L, et al. Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. Int J Cancer 2010;126:930-9.
27. Boland CR. Moshe Shike. Report from the Jerusalem Workshop on Lynch Syndrome- Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 2010;138:2197-201.
28. Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res 2011;4:1-5.
29. Grover S, Stoffel EM, Bussone L, et al. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2004;2:813-19. (Pubitemid 39200720)
30. Lynch HT, Lynch PM. Molecular screening for the Lynch syndrome-better than family history? N Engl J Med 2005;352:1920-2. (Pubitemid 40627819)
31. Overbeek LI, Ligtenber MJ, Willems RW, et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 2008;32:1246-51.
32. Klarskov L, Ladelund S, Holck S, et al. Interobserver variability in the evaluation of mismatch repair protein immunostaining. Hum Pathol 2010;41:1387-96.
33. Lynch HT, Boland CR, Rodriguez-Bigas MA, et al. Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol 2007; 25:3534-42. (Pubitemid 47310892)
34. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005; 293:1979-85. (Pubitemid 40570891)
35. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer:a cost-effectiveness analysis. Ann Intern Med 2011;155:69-79.